Published
2006.1.1
Issued by
NACB, The National Academy of Clinical Biochemistry
Abstract
The emergence of new technologies and markers often occurs at a much higher velocity that can be captured, validated, put into accepted practice, and reviewed for inclusion in these guidelines. For example, in the prenatal screening area, there is considerable discussion of both second trimester markers such as ITA and Adam 12, but they are not yet in routine practice, in contrast to Inhibin A. The issue of first-trimester screening and nuchal translucency is still being widely discussed. One potential reference is the recent paper by David Wright and Ian Bradbury (BJOG 2005;112:80–83). Commercialization of new markers such as soluble vascular endothelial growth factors and placental growth factors for preeclampsia are also gathering some momentum.More manufacturers have committed to and invested in resources for the development of age-related reference ranges. Even though informed consent requirements have become more daunting, as this goes to press there are several initiatives and studies underway to develop enhanced neonatal and pediatric ranges. Finally, when this guideline was begun, tandem MS/MS was being performed in limited settings. With every year that has passed, more applications and capabilities for assaying not only novel, but routine, biomarkers have come into common practice.
- STUDY RESOURCES
- BINC NEWS
-
INTERVIEW
-
-
13542020/06/30 00:00
-
76472016/05/20 13:53
-
76072016/05/20 15:48
-
- STUDY RESOURCES
-
-
106322019/01/01
-
85952019/02/28
-
79172018/10/31
-